Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for DIMETHYL FUMARATE
- A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
- Study of IMCY-0141 in Recent Onset of Multiple Sclerosis
- Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke
- Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage
- Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke
- Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke
- Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects
- Randomised Evaluation of COVID-19 Therapy
- Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy
- Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
- Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers
- Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
- Melatonin in Patients With Multiple Sclerosis (MS).
- Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis
- A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
- Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients
- Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
- Study of Utilization Patterns of Dimethyl Fumarate in Germany
- Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
- Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008
- Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
- Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate
- Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
- RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
- Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
- Impact of Tecfidera on Gut Microbiota
- Tecfidera Diffusion Tensor Imaging
- Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
- Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
- Tecfidera and MRI for Brain Energy in MS
- Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012
- Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
- Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
- Tecfidera Lymphocyte Chart Review
- Proof-of-concept Study of Forward Pharma (FP)187 in Patients With Mild/Moderate Psoriatic Arthritis
- Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis
- Tecfidera and the Gut Microbiota
- Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis
- Dimethyl Fumarate for Obstructive Sleep Apnea
- BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
- Tecfidera Slow-Titration Study
- Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
- Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
- Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
- Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
- Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.
- Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
- Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
- Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation
- A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers
- Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
- Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
- RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
- Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
- Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis
- Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate
- Dimethyl Fumarate (DMF) Observational Study
- A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
- BG00012 Regional Absorption Study
- PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily
- Biogen Multiple Sclerosis Pregnancy Exposure Registry
- Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
- Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States
- An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
- Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis
- Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
- BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
- BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
- Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
- Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Clinical trials list
click for details